
- Oncology NEWS International Vol 10 No 1
- Volume 10
- Issue 1
NCI Reports Results of Cell Phone-Brain Cancer Study
BETHESDA, Md-The National Cancer Institute has reported results of a study investigating the possible link between brain cancer and cell phone use weeks ahead of its scheduled publication in the New England Journal of Medicine.
BETHESDA, MdThe National Cancer Institute has reported results of a study investigating the possible link between brain cancer and cell phone use weeks ahead of its scheduled publication in the New England Journal of Medicine.
Between 1994 and 1998, researchers collected data from 1,600 patients: 800 had brain tumors and 800 were being treated for a variety of noncancerous conditions.
The results show no link between brain tumors and cell phone use or duration of cell phone use, and no evidence that brain tumors occur more often near where the cell phone is held to the head than on the opposite side.
The exposure to radiation from cell phones among the study participants occurred between the mid-1980s and 1998. This is considered a limitation since the explosion in cellular phone use occurred after the beginning of the study, and relatively few study participants had used a cellular phone for a long time. In addition, study participants used primarily analog phones, while digital phones, which operate at a different frequency and power, are more common today.
In addition to cell phones, the NCI study included the potential dangers of a number of other factors, which will be reported on later.
These included occupational exposures, such as solvents, pesticides, and electromagnetic fields; a family history of cancer; dietary factors, including consumption of processed meats, artificial sweeteners, and vitamin and mineral supplements; past medical problems, including head trauma and radiation exposures; reproductive history and hormone use; and the use of hair dyes.
Articles in this issue
almost 25 years ago
ODAC Recommends Campath for FDA Approval for Refractory CLLalmost 25 years ago
‘IrinoGem’ Active and Well Tolerated in Pancreatic Canceralmost 25 years ago
STI571 Studies Help Validate Molecular Targeting in CMLalmost 25 years ago
Outpatient Mylotarg Therapy Cuts Costs in Relapsed AMLalmost 25 years ago
STI571 Proves Effective in Patients With Interferon-Failure CMLalmost 25 years ago
Prostate Cancer Patients Tolerate Higher 3D Conformal RT Dosesalmost 25 years ago
IP6 (Phytic Acid) Inhibits Breast Cancer in Animalsalmost 25 years ago
Adjuvant Therapy Beneficial in Early, Node-Negative Breast Canceralmost 25 years ago
Medicare Increases Payment Rates for Most Physiciansalmost 25 years ago
Update on High-Dose Consolidation Therapy in Breast CancerNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.